Strategic partnerships Invetech actively collaborates with diagnostics, cell and gene therapy, and medtech players and has recent partnerships with General Fluidics and Trenchant BioSystems. Leverage co-development and contract manufacturing capabilities to position as a preferred end-to-end automation and GMP-ready manufacturing partner for emerging CGT platforms and diagnostics instruments.

Automation leadership Strong focus on end-to-end automation, system integration, and GMP-ready manufacturing. With recent efforts on fully automated AutoCell development and Korus closed systems, target CelGene therapy and autologous processing customers seeking scalable, compliant, and validated manufacturing solutions.

Global and regulatory fit Facilities and certifications include FDA registration plus ISO 13485, ISO 9001, and Class 10,000 cleanroom. This enables selling to U.S. and international biopharma, diagnostics, and device manufacturers requiring robust quality and compliance for scale-up and commercial transfer.

Industry diversity Serves diagnostics, cell and gene therapy, and medtech with capabilities spanning design, automation, software, and manufacturing. Cross-sector expertise allows cross-sell of automated systems, software platforms, and clinical-to-commercial tech transfer services to multiple customer programs.

Growth signals Revenue range indicates mid-market footprint with active partnerships and investments in AI integration and advanced automation. Pursue multi-project deals, expanded scope with existing partners, and expansions into new diagnostics and CGT manufacturing lines to accelerate revenue growth.